Related Experiment Video

Updated: Sep 10, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα

Xiao Liu1, Yanyan Chen2, Wei Han3

  • 1Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, China;

Annual Review of Pharmacology and Toxicology
|August 19, 2025
PubMed

Insights

Targeting Phosphoinositide 3-kinase alpha (PI3Kα) with novel inhibitors shows promise for cancer treatment. New strategies focus on mutant selectivity and reduced toxicity to improve therapeutic outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Phosphoinositide 3-kinase alpha (PI3Kα) is crucial for cell growth and survival.
  • PIK3CA mutations drive the PI3K/AKT/mTOR pathway in many cancers.
  • Existing PI3K inhibitors face challenges with toxicity and resistance.

Purpose of the Study:

  • To review current progress in PI3Kα inhibitor development.
  • To highlight structural characteristics and clinical challenges.
  • To discuss emerging strategies for improved PI3Kα-targeted therapies.

Main Methods:

  • Analysis of structural, biochemical, and computational studies.
  • Review of clinical data for PI3Kα inhibitors.
  • Synthesis of recent breakthroughs in inhibitor design.

Main Results:

  • Mutation-specific conformational changes in PI3Kα are understood.
  • Allosteric, covalent, and degrader inhibitors offer enhanced selectivity.
  • Decoupling antitumor activity from metabolic dysfunction is a key goal.

Conclusions:

  • Future directions include increasing mutant selectivity and exploring new mechanisms of action.
  • Conformational modulation and personalized therapies are vital for PI3Kα drug discovery.
  • Overcoming resistance and toxicity remains critical for clinical success.
Keywords:
PI3Kαallosteric inhibitioncancermutant-selectiveoncogenic mutationsstructural pharmacology

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K